CellFIT
CAR T-cell therapy can be a powerful means of treating cancer, where a patient’s T cells are extracted and modified, before being re-introduced back into the patient to attack cancer cells. Researchers in the CellFit project are working to develop new, more effective methods of producing T cells and assessing their efficacy.
Established in 2021, and funded by The Research Council of Norway, the Cellfit Project seeks to address one of the biggest challenges for cell-based cancer therapy – efficient and scalable production. This process deals with living drugs, which require precise logistics. A central requirement for efficient and cost-effective cellular therapy is that the cellular product needs to persist in the patient.
To improve therapeutic efficacy, increased collaboration between manufacturers (industries) and patient treatment centres (hospitals) is needed. The current products available are not optimal. Focused research aimed at delivering an improved product has not been sufficiently developed. The CellFit Project seeks to provide significantly improved cellular products (more active and in vivo persistent) and processes (higher yields, more streamlined).